Home › Free Stock Grades › PROK
ProKidney Corp. (PROK) Stock Grade
PROK · Healthcare
C
Market Cap
$541.4M
P/E Ratio
—
Revenue Growth (YoY)
+1075.0%
Net Margin
-7725.2%
Return on Equity
6.8%
Dividend Yield
None
About ProKidney Corp.'s fundamentals
ProKidney Corp. is a biotech company with a $541.4M market cap that reported explosive revenue growth of 1,075% year-over-year, indicating significant commercial traction or recent product launches. However, the company is not yet profitable, posting a net loss in its latest annual statement with a net margin of -7,725.2%, reflecting the typical cash-burn pattern of early-stage biotechnology firms. The company does not currently pay a dividend, which is common for pre-profitable biotech companies focusing resources on research and development.